Partial
Mostly Misaligned
Patient Risk:
Info
Summary
Most claims provided concern gastrointestinal bleeding/melena and generalized guidance, but the label excerpts supplied focus only on boxed warning/threats related to premature discontinuation and spinal/epidural anesthesia/puncture. Because those melena-specific claims are not supported by the supplied label text, alignment is partial.
Category Scores
Accurate Statements
Premature discontinuation / spinal-epidural hematoma (related risks)
No corresponding claims were included in the user-provided AI response text; however, the supplied label excerpts do include (1) boxed warning/5.1 about increased thrombotic risk with premature discontinuation and (2) boxed warning/5.3 about spinal/epidural hematoma with neuraxial anesthesia or puncture.
Unsupported Statements
Eliquis (apixaban) is a blood thinner medication used to prevent strokes and blood clots.
Not supported by the provided label excerpts (the supplied text only includes specific warnings/precautions sections and partial indication headers without explicit phrasing matching this claim).
Black stools can be a sign of gastrointestinal bleeding.
Not supported by the provided label excerpts.
Gastrointestinal bleeding can cause black or tarry stools (melena) by mixing blood with bile.
Not supported by the provided label excerpts.
Melena is a rare but serious side effect of blood thinners like Eliquis.
Not supported by the provided label excerpts.
The incidence of melena in patients taking Eliquis is around 1.2% to 1.5%.
Not supported by the provided label excerpts.
The risk of melena with Eliquis can increase in patients with a history of bleeding disorders, recent surgery, or liver problems.
Not supported by the provided label excerpts.
Black stool can be a sign of ulcers, bleeding ulcers, or tears in the gastrointestinal tract.
Not supported by the provided label excerpts.
Untreated gastrointestinal bleeding can lead to anemia, organ damage, and even death.
Not supported by the provided label excerpts.
If a patient taking Eliquis experiences black stools, they should contact their healthcare provider immediately for further evaluation such as an endoscopy or blood tests.
Not supported by the provided label excerpts.
Black stools can occur at any time while taking Eliquis.
Not supported by the provided label excerpts.
The risk of bleeding events, including gastrointestinal bleeding, was highest within the first 30 days of apixaban therapy.
Not supported by the provided label excerpts.
Contradictions
Important Omissions
Key on-label warnings from the supplied label excerpts regarding (a) increased risk of thrombotic events after premature discontinuation and (b) spinal/epidural hematoma risk with neuraxial anesthesia/puncture including monitoring/management timing details (e.g., catheter removal ≥24 hours; next dose ≥5 hours; delay 48 hours after traumatic puncture) were not addressed in the AI response.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Info
The AI response focuses on melena/GI bleeding details that are not supported by the provided label excerpts; it also omits specific boxed warning/neuraxial timing and monitoring instructions present in the supplied labeling. This reduces label alignment but does not, based on the provided excerpts, create a direct contradiction.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Misaligned
Primary Issue
Nearly all claims relate to melena/GI bleeding epidemiology and evaluation guidance, none of which are supported by the supplied Eliquis labeling excerpts (which instead address premature discontinuation and spinal/epidural hematoma).
Suggested Improvement
Limit claims to the provided label-supported boxed warnings/Warnings and Precautions content (premature discontinuation thrombotic risk; neuraxial anesthesia/puncture spinal/epidural hematoma risk) and, if GI bleeding/melena is discussed, ensure the full relevant Eliquis US prescribing information sections (including bleeding/melena incidence, risk factors, and patient guidance) are reviewed and quoted.